GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think about obesity, diabetes and weight loss
3 Overall, GLP-1RAs offer promise in reproductive medicine, particularly for obesity-related infertility
Freezing irreversibly damages the protein structure, rendering the medication ineffective and potentially unsafe
The STEP 8 trial demonstrated similar rates of adverse events for semaglutide and liraglutide, but with less discontinuation due to adverse events with semaglutide [33]
This effect appears to involve modulation of reward pathways and satiety signaling, leading to decreased caloric consumption
29 Antiliraglutide Antibodies: In three of the six phase III LEAD trials, anti-liraglutide antibodies were reported and developed as follows: in 9% to 13% of subjects receiving 0.6 mg to 1.8 mg (LEAD-1)